Patents by Inventor Raymond F. Horvath

Raymond F. Horvath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-substituted-2-arylpyridines
    Patent number: 7223778
    Abstract: Novel 5-substituted-2-arylpyridine compounds are provided. Such compounds can act as selective modulators of CRF receptors. The 5-substituted-2-arylpyridine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: May 29, 2007
    Assignee: Neurogen Corporation
    Inventors: Ge Ping, Taeyoung Yoon, Lu Yan Zhang, Raymond F. Horvath
  • Substituted arylpyrazines
    Patent number: 7202250
    Abstract: Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.
    Type: Grant
    Filed: April 15, 2005
    Date of Patent: April 10, 2007
    Assignee: Neurogen Corporation
    Inventors: Taeyoung Yoon, Ping Ge, Raymond F. Horvath, Stėphane DeLombaert, Kevin J. Hodgetts, Dario Doller, Cunyu Zhang
  • 5-substituted-2-arylpyrazines
    Patent number: 7179807
    Abstract: Novel 5-substituted-2-arylpyrazine compounds are provided. Such compounds can act as selective modulators or CRF receptors. Compounds of the invention are provided by the following formula: The 5-substituted-2-arylpyrazine compounds provided herein are useful in the treatment of a number of CNS and periphercal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: February 20, 2007
    Assignee: Neurogen Corporation
    Inventors: Taeyoung Yoon, Ping Ge, Stéphane De Lombaert, Raymond F. Horvath, Dario Doller, Kevin J. Hodgetts, Lu Yan Zhang, Bernd Kaiser, Xuechun Zhang, Yasuchika Yamaguchi, Cunyu Zhang, Jim Darrow
  • Certain alkylene diamine-substituted heterocycles
    Patent number: 7074929
    Abstract: This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: July 11, 2006
    Assignees: Neurogen Corp., Pfizer, Inc.
    Inventors: Raymond F. Horvath, Jennifer Tran, Stéphane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
  • Substituted arylpyrazines
    Patent number: 6995161
    Abstract: Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: February 7, 2006
    Assignee: Neurogen Corporation
    Inventors: Taeyoung Yoon, Ping Ge, Raymond F. Horvath, Stephane DeLombaert, Kevin J. Hodgetts, Dario Doller, Cunyu Zhang
  • Certain alkylene diamine-substituted heterocycles
    Publication number: 20040229870
    Abstract: The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor.
    Type: Application
    Filed: November 10, 2003
    Publication date: November 18, 2004
    Applicants: NEUROGEN CORPORATION, PFIZER INC.
    Inventors: Raymond F. Horvath, Jennifer N. Tran, Stephane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
  • Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
    Patent number: 6797824
    Abstract: Disclosed are compounds of the formula: wherein R1 represents optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl groups; X, Z, and Y are optionally substituted nitrogen or carbon atoms; R3 and R4 are organic or inorganic substitutents which may together form ring structutes; m is zero, one or two; and R5 and R6 are are organic or inorganic substituents; and the pharmaceutically acceptable addition salts thereof, which compounds are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: September 28, 2004
    Assignee: Neurogen Corporation
    Inventors: Andrew Thurkauf, Raymond F. Horvath, Jun Yuan, John M. Peterson
  • 5-Substituted-2-arylpyrazines
    Publication number: 20040106620
    Abstract: Novel 5-substituted-2-arylpyrazine compounds are provided. Such compounds can act as selective modulators of CRF receptors. The 5-substituted-2-arylpyrazine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided.
    Type: Application
    Filed: August 20, 2003
    Publication date: June 3, 2004
    Applicant: Neurogen Corporation
    Inventors: Taeyoung Yoon, Ping Ge, Stephane DeLombaert, Raymond F. Horvath
  • Certain alkylene diamine-substituted heterocycles
    Patent number: 6696445
    Abstract: The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. The present invention provides novel, potent, non-peptidic antagonists of NPY receptors, particularly, the NPY1 receptors, designed from a selection of mono-, bi-, or tri-cyclic heterocyclic cores. This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. The novel compounds encompassed by the present invention are those of the formula I-XV.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: February 24, 2004
    Assignees: Neurogen Corporation, Pfizer Inc.
    Inventors: Raymond F. Horvath, Jennifer N Tran, Stéphane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
  • Certain pyrrolopyridine derivatives: novel CRF1 specific ligands
    Patent number: 6670371
    Abstract: Disclosed are compounds of the formula: wherein Ar is optionally substituted aryl or heteroaryl R1 is hydrogen or alkyl; R7 is hydrogen or alkyl; R2 is hydrogen, halogen, alkyl or alkoxy; or R1 and R2 taken together with the ring to which they are attached form a 5-9 membered saturated or aromatic ring optionally having a hetero atom selected from oxygen, sulfur or nitrogen; R3 and R4 are independently hydrogen, alkyl, cycloalkyl, aryl or heteroaryl groups; or R3 and R4 together with the nitrogen atom to which they are attached form a 5-8 membered ring; and R5 is hydrogen, halogen, straight or branched chain lower alkyl having 1-6 carbon atoms, or straight or branched chain lower alkoxy or thioalkoxy having 1-6 carbon atoms, which compounds are highly selective partial agonists or antagonists at human Corticotropin-Releasing Factor 1 (CRF1) receptors and are useful in the diagnosis and treatment of treating stress related disorders such as post trumatic stress disorder (PTSD) as wel
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: December 30, 2003
    Assignee: Neurogen Corporation
    Inventors: Raymond F. Horvath, Alan Hutchison
  • Certain alkylene diamine-substituted heterocycles
    Publication number: 20030158197
    Abstract: The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor.
    Type: Application
    Filed: November 8, 2002
    Publication date: August 21, 2003
    Applicant: NEUROGEN CORPORATION
    Inventors: Raymond F. Horvath, Jennifer N. Tran, Stephane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
  • 5-Substituted-2-arylpyridines
    Publication number: 20030152520
    Abstract: Novel 5-substituted-2-arylpyridine compounds are provided. Such compounds can act as selective modulators of CRF receptors. The 5-substituted-2-arylpyridine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided.
    Type: Application
    Filed: May 22, 2002
    Publication date: August 14, 2003
    Applicant: Neurogen Corporation
    Inventors: Ping GE, Taeyoung Yoon, Lu Yan Zhang, Raymond F. Horvath
  • N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
    Patent number: 6583169
    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein; A is N or CH; R1 and R2 represents hydrogen or lower alkyl; G, R3, R4, R5, R6, R7 and R8 are variables defined herein. These compounds are modulators of CRF receptors and are therefore useful for treating affective disorders, anxiety, depression, eating disorders, and stress disorders in humans and other animals. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: June 24, 2003
    Assignee: Neurogen Corporation
    Inventors: Raymond F. Horvath, Ping Ge, Taeyoung Yoon, Alan Hutchison
  • Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino[2,3-b]indole and 5,6,7,8-tetrahydro-9H-pyrimidino[4,5-b]indole derivatives: CRF1 specific ligands
    Publication number: 20030105117
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: August 27, 2002
    Publication date: June 5, 2003
    Applicant: Neurogen Corporation
    Inventors: Raymond F. Horvath, James W. Darrow, George D. Maynard
  • Benzimidazole and indole derivatives as CRF receptor modulators
    Publication number: 20030055037
    Abstract: Benzimidazole and indole derivatives that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided.
    Type: Application
    Filed: October 5, 2001
    Publication date: March 20, 2003
    Inventors: Stephane DeLombaert, Ping Ge, Raymond F. Horvath, Taeyoung Yoon
  • Substituted arylpyrazines
    Publication number: 20030018035
    Abstract: Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.
    Type: Application
    Filed: February 16, 2001
    Publication date: January 23, 2003
    Inventors: Taeyoung Yoon, Ping Ge, Raymond F. Horvath, Stephane DeLombaert, Kevin J. Hodgetts, Dario Doller, Cunyu Zhang
  • Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
    Publication number: 20030018025
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: May 28, 2002
    Publication date: January 23, 2003
    Applicant: Neurogen Corporation, Corporation of the State of Delaware
    Inventors: Andrew Thurkauf, Raymond F. Horvath, Jun Yuan, John M. Peterson
  • Certain alkylene diamine-substituted heterocycles
    Patent number: 6506762
    Abstract: The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. The present invention provides novel, potent, non-peptidic antagonists of NPY receptors, particularly, the NPY1 receptors, designed from a selection of mono-, bi-, or tri-cyclic heterocyclic cores. This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. The novel compounds encompassed by the present invention are those of the formula I-XV.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: January 14, 2003
    Assignees: Neurogen Corporation, Pfizer Inc.
    Inventors: Raymond F. Horvath, Jennifer Tran, Stéphane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
  • Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
    Patent number: 6472402
    Abstract: Disclosed are compounds of the formula: wherein Ar, R1, W, X and m are substituents as defined herein.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: October 29, 2002
    Assignee: Neurogen Corporation
    Inventors: Raymond F. Horvath, James W. Darrow, George D. Maynard
  • Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
    Publication number: 20020143044
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: March 18, 2002
    Publication date: October 3, 2002
    Applicant: Neurogen Corporation
    Inventors: Andrew Thurkauf, Raymond F. Horvath, Jun Yuan, John M. Peterson